Growth trajectory CardioCare platform is expanding nationwide with enhancements and a new UI, signaling increased adoption across more structural heart and cardiovascular programs and creating cross-sell opportunities with hospitals expanding cardiovascular AI capabilities.

Executive credibility Led by an experienced AI and big data leadership team with recognition from Fast Company, positioning the company as a trusted partner for health systems seeking advanced analytics for patient risk identification and treatment pathways.

Clinical partnerships New medical advisory board appointments and collaboration announcements with industry experts indicate opportunities to co-develop validated clinical use cases and upsell to health systems seeking evidence-backed AI tools.

Platform integration Recent and upcoming integrations with Continuum and existing health tech ecosystems (EquiSoft, Mako, VieFUND, Learnedly) create a pathway to embed CardioCare within hospital IT ecosystems, enabling easier procurement and deployment.

Data-driven expansion Lp(a) patient identification capability and large-scale data insights for cardiology programs suggest upsell potential to programs focusing on biomarker-driven risk stratification and research-oriented CardioCare research suites.